[go: up one dir, main page]

AU2002242910A1 - Medicaments which are modulators of hm74 and/or hm74a activity - Google Patents

Medicaments which are modulators of hm74 and/or hm74a activity

Info

Publication number
AU2002242910A1
AU2002242910A1 AU2002242910A AU2002242910A AU2002242910A1 AU 2002242910 A1 AU2002242910 A1 AU 2002242910A1 AU 2002242910 A AU2002242910 A AU 2002242910A AU 2002242910 A AU2002242910 A AU 2002242910A AU 2002242910 A1 AU2002242910 A1 AU 2002242910A1
Authority
AU
Australia
Prior art keywords
hm74a
medicaments
modulators
activity
hm74a activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002242910A
Inventor
Steven Michael Foord
Nicholas Brian Pike
Alan Wise
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0109028A external-priority patent/GB0109028D0/en
Priority claimed from GB0126637A external-priority patent/GB0126637D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2002242910A1 publication Critical patent/AU2002242910A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002242910A 2001-04-11 2002-04-10 Medicaments which are modulators of hm74 and/or hm74a activity Abandoned AU2002242910A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0109028A GB0109028D0 (en) 2001-04-11 2001-04-11 Medicaments
GB0109028.1 2001-04-11
GB0126637A GB0126637D0 (en) 2001-11-06 2001-11-06 Medicaments
GB0126637.8 2001-11-06
PCT/GB2002/001671 WO2002084298A2 (en) 2001-04-11 2002-04-10 Medicaments which are modulators of hm74 and/or hm74a activity

Publications (1)

Publication Number Publication Date
AU2002242910A1 true AU2002242910A1 (en) 2002-10-28

Family

ID=26245958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002242910A Abandoned AU2002242910A1 (en) 2001-04-11 2002-04-10 Medicaments which are modulators of hm74 and/or hm74a activity

Country Status (4)

Country Link
US (1) US20040254224A1 (en)
EP (1) EP1377834A2 (en)
AU (1) AU2002242910A1 (en)
WO (1) WO2002084298A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
DE10251244A1 (en) * 2002-11-04 2004-05-19 Universität Heidelberg Method for detecting compounds with antihyperlipemic activity, useful for identifying therapeutic agents, is based on their interaction with nicotinic acid receptors
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
US7465548B2 (en) 2003-02-17 2008-12-16 Bayer Healthcare Ag Methods of screening for potential therapeutics for diseases associated with G-protein coupled receptor HM74a
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
US20050003405A1 (en) * 2003-04-30 2005-01-06 Hua-Chien Chen Treatment and diagnostics of cancer
AR041089A1 (en) 2003-05-15 2005-05-04 Merck & Co Inc PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS
GB0319126D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
DK1781657T3 (en) 2004-02-14 2013-06-10 Glaxosmithkline Ip Dev Ltd MEDICINES WITH HM74A RECEPTOR ACTIVITY
US20060078916A1 (en) * 2004-08-27 2006-04-13 Luc Aguilar HM74 and HM74a in cuboidal endothelial cells as associated with inflammation
WO2006045564A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
MX2007004882A (en) * 2004-10-22 2007-05-09 Smithkline Beecham Corp Xanthine derivatives with hm74a receptor activity.
AR054998A1 (en) 2004-12-03 2007-08-01 Schering Corp PIPERAZINAS REPLACED AS AN ANCHANGIST OF CB1, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND FOR THE MANUFACTURE OF MEDICINES
GB0503056D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
JP2008538277A (en) * 2005-02-18 2008-10-23 アリーナ ファーマシューティカルズ， インコーポレイテッド Compositions and methods for the treatment of lipid related disorders
US7723342B2 (en) 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
SI1901731T1 (en) 2005-06-28 2011-07-29 Merck Sharp & Dohme Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP2272848B1 (en) 2005-08-10 2012-12-26 Glaxosmithkline LLC Xanthine derivatives as selective HM74A agonists
CA2628401A1 (en) * 2005-12-07 2007-06-14 Boehringer Ingelheim International Gmbh Treatment and diagnostics of inflammatory diseases
US7897601B2 (en) * 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
CA2637717A1 (en) 2006-01-20 2007-08-02 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
TWI423978B (en) 2006-06-23 2014-01-21 Incyte Corp Purinone derivatives as hm74a agonists
KR20090025261A (en) 2006-06-23 2009-03-10 인사이트 코포레이션 Purinone Derivatives as HM7４A Agonists
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
EP2170846A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
CA2694264A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007563A4 (en) * 1997-06-12 2003-04-16 Smithkline Beecham Corp Hm74a receptor
US6031090A (en) * 1998-08-07 2000-02-29 Smithkline Beecham Corporation Molecular cloning of a 7TM receptor (GPR31A)
GB0003898D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
EP1292677A2 (en) * 2000-06-05 2003-03-19 Bayer Aktiengesellschaft Human hm74-like g protein coupled receptor

Also Published As

Publication number Publication date
WO2002084298A2 (en) 2002-10-24
US20040254224A1 (en) 2004-12-16
EP1377834A2 (en) 2004-01-07
WO2002084298A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
AU2002242910A1 (en) Medicaments which are modulators of hm74 and/or hm74a activity
AU2002320185A1 (en) Biological activity of ak155
AU2002366103A1 (en) Modulators of rho c activity
AU2002241520A1 (en) Blood assessment of injury
MX242714B (en) Synthesis and purification of valacyclovir.
AU2002330095A1 (en) Flavonoids for treatment of diabetes
AU1356201A (en) Treatment of hyperproliferative disorders
AU2002238688A1 (en) Aryl carbamate derivatives, preparation and use thereof
AU2432001A (en) Treatment of mental conditions including depression
AU2001245414A1 (en) Treatment of allergies
AU2002360405A1 (en) Modulators of rho c activity
AU2002356981A1 (en) Modulators of rho c activity
AU2003227601A1 (en) Production of polyoxymethylene and suitable (iii) catalysts
AU2002327440A1 (en) Treatment of type i diabetes
AU2002359428A1 (en) Modulators of rho c activity
AU2002308105A1 (en) Benzoaxathiepin derivatives and their use as medicines
AU2003229640A1 (en) Production of polyoxymethylene and suitable (ii) catalysts
AU2003227602A1 (en) Production of polyoxymethylene and suitable catalysts
AU2003230064A1 (en) Hepatoprotective activity of 10-o-p-hydroxybenzoyiaucubin
AU2002360957A1 (en) Heterogenisation of catalytic components
AU2003205088A1 (en) Modulation of cop9 signalsome isopeptidase activity
AU2002215923A1 (en) Use of medicaments
AU2002323746A1 (en) Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
AU2002249107A1 (en) Use of chitosan microcapsules
AU2002324392A1 (en) Personal medication and health aid

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase